Healthcare entity
All 2 tracked stories fall under one category: regulation. FDA is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Source depth averages 6 original sources per story, versus 2.4 across the same-window beat baseline. At 7, the average consequence score sits above the same-window beat average of 5.8.
Last mentioned: Mar 24, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 2 tracked stories fall under one category: regulation. FDA is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Source depth averages 6 original sources per story, versus 2.4 across the same-window beat baseline. At 7, the average consequence score sits above the same-window beat average of 5.8. We currently track 2 Healthcare stories that mention Guttmacher Institute, all published on March 24, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 29 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Guttmacher Institute. Shared-story counts are live from our verified record — not editorial picks.
Current Data Release
National reports show abortion numbers holding steady despite 14+ state bans.
Medication Dominance
FDA data confirms medication abortion surpasses surgical procedures as the primary method.
Supreme Court Ruling
SCOTUS maintains access to mifepristone by dismissing a challenge to FDA's rules on procedural grounds.
Shield Law Expansion
States like MA and NY pass laws protecting telehealth providers mailing pills to ban states.
Pharmacy Certification
FDA updates REMS to allow retail pharmacies to dispense mifepristone upon certification.
Dobbs Decision
U.S. Supreme Court overturns Roe v. Wade, allowing state-level bans.
Mail-Order Authorization
FDA permanently removes the requirement for in-person dispensing, allowing for telehealth and mail delivery.
Protocol Expansion
FDA extends usage window to 10 weeks and reduces required office visits from three to one.
Initial FDA Approval
FDA approves mifepristone for medical termination of pregnancy through seven weeks.
Medication abortion now accounts for the majority of pregnancy terminations in the United States, driven by the expansion of telehealth and mail-order pharmacy access. This shift has sparked a sophisticated regulatory counter-offensive from opponents targeting FDA-approved protocols and cross-state digital health providers.
New data reveals that the total number of abortions in the United States has remained stable despite a wave of state-level bans and restrictions. This trend is largely driven by the rapid expansion of telehealth services and medication abortion, highlighting a significant shift in how reproductive healthcare is delivered and regulated.
Guttmacher Institute is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
